[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022

Drug Name: Dorzagliatin

Drug Modality: Small Molecule

Drug Target:  GKA (Glucokinase Activator )

Developed By：Hua Medicine

Approved Date: 2022-10 by China NMPA

Indication: Type 2 diabetes

Dosage Form and Strength: Tablets, 75 mg

.

.

Product Code: HMS5552

Chinese Name of “Dorzagliatin”, 多格列艾汀

Chinese Name of “Hua Medicine”, 华领医药